Loading...
•
Jun 30
Repare Therapeutics Q2 2025 Earnings Report
Repare Therapeutics reported Q2 2025 results with $0.25M revenue and a net loss of $16.7M.
Key Takeaways
Revenue was $250,000 from collaboration agreements; operating loss was $17.8M and net loss was $16.7M (EPS -$0.39). Cash and cash equivalents were $67.7M, with $109.5M including marketable securities.
Revenue for the quarter was $250,000 from collaboration agreements.
Net loss totaled $16.7M with EPS of -$0.39.
R&D expense was $14.3M and G&A was $6.0M; restructuring expense was $3.4M.
Cash, cash equivalents, and marketable securities totaled $109.5M as of June 30, 2025.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Company expects initial topline data from the LIONS (RP-1664) and POLAR (RP-3467) trials in Q4 2025; continues to explore strategic alternatives and advance partnerships, including a new worldwide licensing agreement for lunresertib.
Positive Outlook
- Initial data from LIONS trial expected in Q4 2025.
- Topline safety/tolerability and early efficacy data from POLAR expected in Q4 2025.
- Exclusive worldwide licensing agreement with Debiopharm for lunresertib, including upfront and milestone potential.
- Amended BMS collaboration added an additional druggable target.
- Active exploration of strategic partnerships and sale opportunities across the portfolio.
Challenges Ahead
- No quantitative revenue or earnings guidance provided for upcoming quarters.
- Clinical milestones concentrated in Q4 2025, leaving near-term catalysts limited.
- Continuing operating and net losses highlight ongoing cash burn.
- Restructuring expenses impacted the quarter.
- Future economics from partnerships (e.g., single-digit royalties) may be modest relative to costs.